The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial

Home | Video pages | Webcast | The impact of novel anticancer therapies on blood pressure and kidney function in patients with CKD

The impact of novel anticancer therapies on blood pressure and kidney function in patients with CKD